$UNCY News

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Unicycive Therapeutics Receives FDA Acceptance Of Its NDA Resubmission For Oxylanthanum Carbonate For Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis

Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Unicycive Therapeutics Appoints Meredith Manning to Board of Directors

HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

Unicycive Therapeutics Resubmits Its FDA New Drug Application For Oxylanthanum Carbonate For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Expects PDUFA Date Six Months From Resubmission Date

Unicycive Says Suit Alleges Securities Law Violations Over Statements On Oxylanthanum Carbonate FDA Application

Unicycive Therapeutics Discloses Securities Class Action Filed September 3 Against Company And Certain Officers

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

Unicycive Therapeutics shares rise after second-quarter loss beats forecasts

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate

Unicycive Therapeutics: Two CRLs, One Fixable Problem

Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13